Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer

In Vivo. 2019 Mar-Apr;33(2):477-482. doi: 10.21873/invivo.11498.

Abstract

Background/aim: A phase II trial was conducted to assess the efficacy and safety of gefitinib plus bevacizumab for EGFR mutation-positive non-small cell lung cancer (NSCLC).

Patients and methods: Patients were randomly assigned to receive either gefitinib at 250 mg/day alone or with bevacizumab at 15 mg/kg every 3 weeks.

Results: Ten patients were allocated to the gefitinib group (group A) and 6 to the gefitinib plus bevacizumab group (group B). Median survival time (80%CI) for progression-free survival (PFS) was 15.1 months for group A, and 5.4 months for group B. Overall survival probability at 1 year (95%CI) was 0.750 for group A, and 0.667 for group B. The response rate was 44 % for group A and 50 % for group B. Adverse events occurred at a similar frequency in both groups.

Conclusion: PFS was shorter in group B than group A, and therefore there was no basis to proceed to a phase III trial.

Keywords: EGFR-TKI; NSCLC; VEGF inhibitor; bevacizumab; gefitinib.

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Bevacizumab / administration & dosage*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • ErbB Receptors / genetics
  • Female
  • Gefitinib / administration & dosage*
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Mutation
  • Progression-Free Survival
  • Protein Kinase Inhibitors / administration & dosage

Substances

  • Protein Kinase Inhibitors
  • Bevacizumab
  • EGFR protein, human
  • ErbB Receptors
  • Gefitinib